Sequencing Abiraterone and Enzalutamide in mCRPC
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses sequencing abiraterone and enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Clinical Pearls
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses sequencing abiraterone and enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
- This study is a retrospective analysis aiming to characterize the activity of abiraterone following enzalutamide and vice versa
- Data sets like these are becoming increasingly important and speak to potential resistance that evolves when a patient receives one drug or the other for mCRPC
- This study, as well as others, have shown that receiving one drug may compromise the efficacy of the second
Related Videos
Related Content
